Global Intravenous (IV) Iron Drugs Market: Forecast to 2022

Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic

Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022) • By Region- North America, Europe, APAC and RoW • By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan, Brazil and South Africa • Company Analysis

(c) AZOTH Analytics

January 2018

Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)  Scope of the Study

 Global Coverage  Regional Coverage  Country Coverage

Global Coverage

Regional Coverage    

 Global IV Iron Drug Market Market (2012-2016), By Value  Global IV Iron Drug Market Market (2017-2022), By Value  Breakdown-By Therapeutic Application  Global IV Iron Drug Market Market (2012-16), By Value  Global IV Iron Drug Market (2017-22),

By Value  Breakdown-By Product Type  Global IV Iron Drug Market (20122016), By Product Type, By Value  Global IV Iron Drug Market (20172022), By Product Type, By Value

Segment Coverage  Global IV Iron Drug Market – By Product Type (Ferric carboxymaltose, Sucrose, Dextran and Others), By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others)

North America Europe Asia Pacific R.O.W

Country Coverage          

 IV Iron Drug Market, By Therapeutic Application (20122022)  IV Iron Drug Market, By Product Type (2012-2022)

United States Canada United Kingdom Germany France China Japan India Brazil South Africa

 IV Iron Drug Market Market, By Value (2012-2022)  IV Iron Drug Market Market, By Value (2012-2022)

(c) AZOTH Analytics

Company Coverage

    

Galenica AMAG Pharmaceuticals, Inc PHARMACOSMOS A/S Allergan PLC DAIICHI SANKYO COMPANY, LIMITED  NIPPON SHINYAKU CO.,LTD  Sanofi

 Product Benchmarking  Policy and Regulatory Landscape  Financial Analysis  Sales  EBITDA  PAT  PBT  Business Strategy

2

Table of Content S.No

Particulars

Page No.

1.

Research Methodology

27

2.

Executive Summary

28

3.

Strategic Recommendation

29

3.1

Asia Pacific Region to witness the fastest growth for I.V. Iron drug in the forecast period

30

3.2

Oncology & cardiology segments are witnessing fastest growth

31

4.

I.V. Iron Drug Market Outlook

32

5.

Global I.V. Iron Drug Market: Growth and Forecast

40

5.1

I.V. Iron Drug Market, By Value (2012-2016)

42

5.2

I.V. Iron Drug Market, By Value (2017-2022)

47

5.3

Global I.V. Iron Drug & Market - By Therapeutic Application, By Value

48

5.3.1

I.V. Iron Drug, By Value, % (2016)

48

5.3.2

I.V. Iron Drug, By Value, % (Forecast 2022F)

49

5.4

Global I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

50

5.4.1

Nephrology, By Value (2012-2022)

50

5.4.2

Gynecology & Obstetrics, By Value (2012-2022)

50

5.4.3

Gastroenterology, By Value (2012-2022)

50

5.4.4

Oncology, By Value (2012-2022)

50

5.4.5

Cardiology, By Value (2012-2022)

50

5.4.6

Others, By Value (2012-2022)

50

(c) AZOTH Analytics

3

Table of Content Particulars 5.5

6.

North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)

Page No. 53

5.5.1

Ferric carboxymaltose, By Value (2012-2022)

53

5.5.2

Iron Sucrose, By Value (2012-2022)

53

5.5.3

Iron Dextran

53

5.5.4

Others

53

North America I.V. Iron Drug Market: Growth and Forecast

55

6.1

I.V. Iron Drug Market, By Value (2012-2016)

56

6.2

I.V. Iron Drug Market, By Value (2017-2022)

59

6.3

North America I.V. Iron Drug &

60

6.4

Market - By Therapeutic Application, By Value

6.3.1

I.V. Iron Drug, By Value, % (2016)

60

6.3.2

I.V. Iron Drug, By Value, % (Forecast 2022F)

61

North America I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

62

6.4.1

Nephrology, By Value (2012-2022)

62

6.4.2

Gynecology & Obstetrics, By Value (2012-2022)

62

6.4.3

Gastroenterology, By Value (2012-2022)

62

6.4.4

Oncology, By Value (2012-2022)

62

6.4.5

Cardiology, By Value (2012-2022)

62

6.4.6

Others, By Value (2012-2022)

62

(c) AZOTH Analytics

4

Table of Content S. No

Particulars 6.5

6.6

6.7

6.8

6.9

North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)

Page No. 64

6.5.1

Ferric carboxymaltose, By Value (2012-2022)

64

6.5.2

Iron Sucrose, By Value (2012-2022)

64

6.5.3

Iron Dextran

64

6.5.4

Others

64

North America I.V. Iron Drug Market: Country Analysis (U.S., Canada)

65

6.6.1

North America I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)

65

6.6.2

North America I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

65

U.S. I.V. Iron Drug Market: Growth and Forecast

66

6.7.1

U.S. I.V. Iron Drug Market, By Value (2012-2016)

66

6.7.2

U.S. I.V. Iron Drug Market, By Value (2017-2022)

66

U.S. I.V. Iron Drug & Market - By Therapeutic Application, By Value

70

6.8.1

I.V. Iron Drug, By Value, % (2016)

70

6.8.2

I.V. Iron Drug, By Value, % (Forecast 2022F)

71

U.S. I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

72

6.9.1

Nephrology, By Value (2012-2022)

72

6.9.2

Gynecology & Obstetrics, By Value (2012-2022)

72

(c) AZOTH Analytics

5

Table of Content S. No

Particulars

6.10

6.11

6.12

Page No.

6.9.3

Gastroenterology, By Value (2012-2022)

72

6.9.4

Oncology, By Value (2012-2022)

72

6.9.5

Cardiology, By Value (2012-2022)

72

6.9.6

Others, By Value (2012-2022)

72

Canada I.V. Iron Drug Market: Growth and Forecast

75

6.10.1

Canada I.V. Iron Drug Market, By Value (2012-2016)

75

6.10.2

Canada I.V. Iron Drug Market, By Value (2017-2022)

75

Canada I.V. Iron Drug Market - By Therapeutic Application, By Value

80

6.11.1

I.V. Iron Drug , By Value, % (2016)

80

6.11.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

81

Canada I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

82

6.12.1

Nephrology, By Value (2012-2022)

82

6.12.2

Gynecology & Obstetrics, By Value (2012-2022)

82

6.12.3

Gastroenterology, By Value (2012-2022)

82

6.12.4

Oncology, By Value (2012-2022)

82

6.12.5

Cardiology, By Value (2012-2022)

82

6.12.6

Others, By Value (2012-2022)

82

(c) AZOTH Analytics

6

Table of Content S.No 7.

Particulars Europe I.V. Iron Drug Market: Growth and Forecast

Page No. 84

7.1

I.V. Iron Drug Market, By Value (2012-2016)

85

7.2

I.V. Iron Drug Market, By Value (2017-2022)

85

7.3

Europe I.V. Iron Drug &

89

7.4

Market - By Therapeutic Application, By Value

7.3.1

I.V. Iron Drug , By Value, % (2016)

89

7.3.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

90

Europe I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

91

7.4.1

Nephrology, By Value (2012-2022)

91

7.4.2

Gynecology & Obstetrics, By Value (2012-2022)

91

7.4.3

Gastroenterology, By Value (2012-2022)

91

7.4.4

Oncology, By Value (2012-2022)

91

7.4.5

Cardiology, By Value (2012-2022)

91

7.4.6

Others, By Value (2012-2022)

91

(c) AZOTH Analytics

7

Table of Content S. No

Particulars 7.5

7.6

7.7

7.8

7.9

Europe I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)

Page No. 93

7.5.1

Ferric carboxymaltose, By Value (2012-2022)

93

7.5.2

Iron Sucrose, By Value (2012-2022)

93

7.5.3

Iron Dextran

93

7.5.4

Others

93

Europe I.V. Iron Drug Market: Country Analysis (U.K., Germany, France, Rest of Europe)

95

7.6.1

Europe I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)

95

7.6.2

Europe I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

95

U.K. I.V. Iron Drug Market: Growth and Forecast

96

7.7.1

U.K. I.V. Iron Drug Market, By Value (2012-2016)

96

7.7.2

U.K. I.V. Iron Drug Market, By Value (2017-2022)

96

U.K. I.V. Iron Drug & Market - By Therapeutic Application, By Value

98

7.8.1

I.V. Iron Drug , By Value, % (2016)

98

7.8.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

99

U.K. I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

100

7.9.1

Nephrology, By Value (2012-2022)

100

7.9.2

Gynecology & Obstetrics, By Value (2012-2022)

100

(c) AZOTH Analytics

8

Table of Content S. No

Particulars

7.10

7.11

7.12

Page No.

7.9.3

Gastroenterology, By Value (2012-2022)

100

7.9.4

Oncology, By Value (2012-2022)

100

7.9.5

Cardiology, By Value (2012-2022)

100

7.9.6

Others, By Value (2012-2022)

100

Germany I.V. Iron Drug Market: Growth and Forecast

102

7.10.1

Germany I.V. Iron Drug Market, By Value (2012-2016)

102

7.10.2

Germany I.V. Iron Drug Market, By Value (2017-2022)

102

Germany I.V. Iron Drug Market - By Therapeutic Application, By Value

104

7.11.1

I.V. Iron Drug , By Value, % (2016)

104

7.11.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

105

Germany I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

106

7.12.1

Nephrology, By Value (2012-2022)

106

7.12.2

Gynecology & Obstetrics, By Value (2012-2022)

106

7.12.3

Gastroenterology, By Value (2012-2022)

106

7.12.4

Oncology, By Value (2012-2022)

106

7.12.5

Cardiology, By Value (2012-2022)

106

7.12.6

Others, By Value (2012-2022)

106

(c) AZOTH Analytics

9

Table of Content S. No

Particulars 7.13

7.14

7.15

7.16

France I.V. Iron Drug Market: Growth and Forecast

Page No. 108

7.13.1

France I.V. Iron Drug Market, By Value (2012-2016)

108

7.13.2

France I.V. Iron Drug Market, By Value (2017-2022)

108

France I.V. Iron Drug Market - By Therapeutic Application, By Value

110

7.14.1

I.V. Iron Drug , By Value, % (2016)

110

7.14.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

111

France I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

112

7.15.1

Nephrology, By Value (2012-2022)

112

7.15.2

Gynecology & Obstetrics, By Value (2012-2022)

112

7.15.3

Gastroenterology, By Value (2012-2022)

112

7.15.4

Oncology, By Value (2012-2022)

112

7.15.5

Cardiology, By Value (2012-2022)

112

7.15.6

Others, By Value (2012-2022)

112

Rest of Europe I.V. Iron Drug Market: Growth and Forecast

114

7.16.1

Rest of Europe I.V. Iron Drug Market, By Value (2012-2016)

114

7.16.2

Rest of Europe I.V. Iron Drug Market, By Value (2017-2022)

114

(c) AZOTH Analytics

10

Table of Content S.No

8.

Particulars

Asia Pacific I.V. Iron Drug Market: Growth and Forecast

Page No.

115

8.1

I.V. Iron Drug Market, By Value (2012-2016)

116

8.2

I.V. Iron Drug Market, By Value (2017-2022)

117

8.3

Asia Pacific I.V. Iron Drug &

118

8.4

Market - By Therapeutic Application, By Value

8.3.1

I.V. Iron Drug , By Value, % (2016)

118

8.3.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

119

Asia Pacific I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)

120

8.4.1

Nephrology, By Value (2012-2022)

120

8.4.2

Gynecology & Obstetrics, By Value (2012-2022)

120

8.4.3

Gastroenterology, By Value (2012-2022)

120

8.4.4

Oncology, By Value (2012-2022)

120

8.4.5

Cardiology, By Value (2012-2022)

120

8.4.6

Others, By Value (2012-2022)

120

(c) AZOTH Analytics

11

Table of Content S. No

Particulars 8.5

8.6

8.7

8.8

8.9

Asia Pacific I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)

Page No. 122

8.5.1

Ferric carboxymaltose, By Value (2012-2022)

122

8.5.2

Iron Sucrose, By Value (2012-2022)

122

8.5.3

Iron Dextran

122

8.5.4

Others

122

Asia Pacific I.V. Iron Drug Market: Country Analysis (Japan, China, India, Rest of Asia-Pacific)

123

8.6.1

Asia Pacific I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)

123

8.6.2

Asia Pacific I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

123

Japan I.V. Iron Drug Market: Growth and Forecast

124

8.7.1

Japan I.V. Iron Drug Market, By Value (2012-2016)

124

8.7.2

Japan I.V. Iron Drug Market, By Value (2017-2022)

124

Japan I.V. Iron Drug & Market - By Therapeutic Application, By Value

126

8.8.1

I.V. Iron Drug , By Value, % (2016)

126

8.8.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

127

Japan I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

128

8.9.1

Nephrology, By Value (2012-2022)

128

8.9.2

Gynecology & Obstetrics, By Value (2012-2022)

128

(c) AZOTH Analytics

12

Table of Content S. No

Particulars

8.10

8.11

8.12

Page No.

8.9.3

Gastroenterology, By Value (2012-2022)

128

8.9.4

Oncology, By Value (2012-2022)

128

8.9.5

Cardiology, By Value (2012-2022)

128

8.9.6

Others, By Value (2012-2022)

128

China I.V. Iron Drug Market: Growth and Forecast

130

8.10.1

China I.V. Iron Drug Market, By Value (2012-2016)

130

8.10.2

China I.V. Iron Drug Market, By Value (2017-2022)

130

China I.V. Iron Drug Market - By Therapeutic Application, By Value

132

8.11.1

I.V. Iron Drug , By Value, % (2016)

132

8.11.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

133

China I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

134

8.12.1

Nephrology, By Value (2012-2022)

134

8.12.2

Gynecology & Obstetrics, By Value (2012-2022)

134

8.12.3

Gastroenterology, By Value (2012-2022)

134

8.12.4

Oncology, By Value (2012-2022)

134

8.12.5

Cardiology, By Value (2012-2022)

134

8.12.6

Others, By Value (2012-2022)

134

(c) AZOTH Analytics

13

Table of Content S. No

Particulars 8.13

8.14

8.15

8.16

India I.V. Iron Drug Market: Growth and Forecast

Page No. 136

8.13.1

India I.V. Iron Drug Market, By Value (2012-2016)

136

8.13.2

India I.V. Iron Drug Market, By Value (2017-2022)

136

India I.V. Iron Drug Market - By Therapeutic Application, By Value

138

8.14.1

I.V. Iron Drug , By Value, % (2016)

138

8.14.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

139

India I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

140

8.15.1

Nephrology, By Value (2012-2022)

140

8.15.2

Gynecology & Obstetrics, By Value (2012-2022)

140

8.15.3

Gastroenterology, By Value (2012-2022)

140

8.15.4

Oncology, By Value (2012-2022)

140

8.15.5

Cardiology, By Value (2012-2022)

140

8.15.6

Others, By Value (2012-2022)

140

Rest of Asia Pacific I.V. Iron Drug Market: Growth and Forecast

142

8.16.1

Rest of Asia Pacific I.V. Iron Drug Market, By Value (2012-2016)

142

8.16.2

Rest of Asia Pacific I.V. Iron Drug Market, By Value (2017-2022)

142

(c) AZOTH Analytics

14

Table of Content S.No

9.

Particulars

ROW I.V. Iron Drug Market: Growth and Forecast

Page No.

143

9.1

I.V. Iron Drug Market, By Value (2012-2016)

144

9.2

I.V. Iron Drug Market, By Value (2017-2022)

145

9.3

ROW I.V. Iron Drug &

146

9.4

Market - By Therapeutic Application, By Value

9.3.1

I.V. Iron Drug , By Value, % (2016)

146

9.3.2

I.V. Iron Drug , By Value, % (Forecast 2022F)

147

ROW I.V. Iron Drug &

Market- By Therapeutic Application, By Value (2012-2022)

148

9.4.1

Nephrology, By Value (2012-2022)

148

9.4.2

Gynecology & Obstetrics, By Value (2012-2022)

148

9.4.3

Gastroenterology, By Value (2012-2022)

148

9.4.4

Oncology, By Value (2012-2022)

148

9.4.5

Cardiology, By Value (2012-2022)

148

9.4.6

Others, By Value (2012-2022)

148

(c) AZOTH Analytics

15

Table of Content S. No

Particulars 9.5

9.6

9.7

9.8

10.

ROW I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)

Page No. 149

9.5.1

Ferric carboxymaltose, By Value (2012-2022)

149

9.5.2

Iron Sucrose, By Value (2012-2022)

149

9.5.3

Iron Dextran

149

9.5.4

Others

149

ROW I.V. Iron Drug Market: Country Analysis (Brazil, South Africa)

150

9.6.1

ROW I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)

150

9.6.2

ROW I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

150

Brazil I.V. Iron Drug Market: Growth and Forecast

151

9.7.1

Brazil I.V. Iron Drug Market, By Value (2012-2016)

151

9.7.2

Brazil I.V. Iron Drug Market, By Value (2017-2022)

151

South Africa I.V. Iron Drug Market: Growth and Forecast

153

9.8.1

South Africa I.V. Iron Drug Market, By Value (2012-2016)

153

9.8.2

South Africa I.V. Iron Drug Market, By Value (2017-2022)

153

Market Dynamics

155

10.1

Increasing Geriatric Population Worldwide

157

10.2

Increasing awareness about the Iron Deficiency diseases

158

(c) AZOTH Analytics

16

Table of Content S. No

Particulars

Page No.

10.3

Rising healthcare expenditure worldwide

159

10.4

Increasing number of dialysis patients

160

10.5

Increasing Life Expectancy

161

11.

Market Restraints

162

12.

SWOT Analysis –Heart Valve Devices Market

169

13.

Porter’s Five Forces Analysis – Heart Valve Devices Market

171

14.

Policy and Regulations

173

15.

Company Profile

181

16.

15.1

Galenica

182

15.2

AMAG Pharmaceuticals, Inc,

185

15.3

PHARMACOSMOS A/S,

187

15.4

Allergan PLC

189

15.5

DAIICHI SANKYO COMPANY, LIMITED,

192

15.6

NIPPON SHINYAKU CO., LTD,

195

15.7

Sanofi

198

About Us

201

(c) AZOTH Analytics

17

List of Figures Figure No.

Figure Title

Page No.

Figure 1:

Causes of premature (under age 70) NCD mortality, 2017 (%)

31

Figure 2:

Global I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)

42

Figure 3:

World Population 65 Years & Above (% of Total), 2012-2016

43

Figure 4:

Life Expectancy at birth rate (Years), 2012-2015

43

Figure 5:

Global Life expectancy at birth, total (years) 2012 -2015

43

Figure 6:

World Female Population, 2012-2016

44

Figure 7:

Global Healthcare Expenditure, 2012-2016 (In Trillion)

44

Figure 8:

Global Potential Patients Numbers, All Indications 2017 (In Million)

45

Figure 9:

Global I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)

47

Figure 10:

Global I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

48

Figure 11:

Global I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

49

Figure 12:

Global I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

50

Figure 13:

Worldwide Dialysis Patients, Numbers (In Million), 2010, 2015, 2020

52

Figure 14:

Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)

53

Figure 15:

Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)

54

Figure 16:

North America I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)

56

Figure 17:

North America Population 65 Years & Above (% of Total), 2012-2016

57

Figure 18:

North America Life Expectancy at birth rate (Years), 2012-2015

57

Figure 19:

North America Women Population, 2012-2016

57

(c) AZOTH Analytics

18

List of Figures Figure No.

Figure Title

Page No.

Figure 20:

North America, Per Capita Healthcare Expenditure, 2012-2014 (In USD)

57

Figure 21:

Population aged 65 & above, 2012-2016 (% of total)

58

Figure 22:

North America I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)

59

Figure 23:

North America I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

60

Figure 24:

North America I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

61

Figure 25:

North America I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

62

Figure 26:

North America I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)

64

Figure 27:

North America I.V. Iron Drug Market, Country Share, 2016 (% of Total)

65

Figure 28:

North America I.V. Iron Drug Market, Country Share, 2022 (% of Total)

65

Figure 29:

U.S. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

66

Figure 30:

U.S. Population 65 Years & Above (% of Total), 2012-2016

68

Figure 31:

U.S. Life Expectancy at birth rate (Years), 2012-2015

68

Figure 32:

U.S. Women Population, 2012-2016

68

Figure 33:

U.S. Per Capita Healthcare Expenditure, 2012-2014 (In Trillion)

68

Figure 34:

United States I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)

69

Figure 35:

U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

71

Figure 36:

U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

72

Figure 37:

U.S. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

73

Figure 38:

Canada I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

75

Figure 39:

Canada Population 65 Years & Above (% of Total), 2012-2016

76

(c) AZOTH Analytics

19

List of Figures Figure No.

Figure Title

Page No.

Figure 40:

Canada Life Expectancy at birth rate (Years), 2012-2015

76

Figure 41:

Canada Life Expectancy at birth rate (Years), 2012-2015

76

Figure 42:

End Stage Kidney Disease patients by Age group, 2012-2015 (Numbers)

77

Figure 43:

Prevalent end-stage kidney disease patients by age group, Canada (excluding Quebec), 2012-2015 (Numbers)

78

Figure 44:

Prevalence rate for patients on dialysis (Excluding Quebec), 2012-2015

79

Figure 45:

Prevalent rate for patients on dialysis or with a functioning transplant in Canada (excluding Quebec), 20122015

79

Figure 46:

Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

80

Figure 47:

Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

81

Figure 48:

Canada I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

82

Figure 49:

Europe I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)

85

Figure 50:

European Union Population 65 Years & Above (% of Total), 2012-2016

86

Figure 51:

European Union Life Expectancy at birth rate (Years), 2012-2015

86

Figure 52:

European Union Women Population, 2012-2016

86

Figure 53:

European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)

86

Figure 54:

European Potential Patients Numbers, All Indications 2017 (In Million)

87

Figure 55:

Europe I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)

88

Figure 56:

Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

89

Figure 57:

Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

90

Figure 58:

Europe I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

91

Figure 59:

Europe I.V. Iron Drug Market - By Product Type, By Value, 2012-2022, (USD Million)

93

Figure 60:

Europe I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)

94

(c) AZOTH Analytics

20

List of Figures Figure No.

Figure Title

Page No.

Figure 61:

Europe I.V. Iron Drug Market, Country Share, 2016 (% of Total)

95

Figure 62:

Europe I.V. Iron Drug Market, Country Share, 2016 (% of Total)

95

Figure 63:

U.K. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

96

Figure 64:

U.K. Population 65 Years & Above (% of Total), 2012-2016

97

Figure 65:

U.K. Life Expectancy at birth rate (Years), 2012-2015

97

Figure 66:

U.K. Women Population, 2012-2016

97

Figure 67:

U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)

97

Figure 68:

U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

98

Figure 69:

U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

99

Figure 70:

U.K. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

100

Figure 71:

Germany I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

102

Figure 72:

Germany Population 65 Years & Above (% of Total), 2012-2016

103

Figure 73:

Germany Life Expectancy at birth rate (Years), 2012-2015

103

Figure 74:

Germany Women Population, 2012-2016

103

Figure 75:

Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)

103

Figure 76:

Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

104

Figure 77:

Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

105

Figure 78:

Germany I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million

106

Figure 79:

France I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

108

Figure 80:

France Population 65 Years & Above (% of Total), 2012-2016

109

(c) AZOTH Analytics

21

List of Figures Figure No.

Figure Title

Page No.

Figure 81:

France Life Expectancy at birth rate (Years), 2012-2015

109

Figure 82:

France Women Population, 2012-2016

109

Figure 83:

France Per Capita Healthcare Expenditure, 2012-2014 (In USD)

109

Figure 84:

France I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

110

Figure 85:

France I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

111

Figure 86:

France I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

112

Figure 87:

Rest of Europe I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

114

Figure 88:

Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)

116

Figure 89:

Asia-Pacific I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)

117

Figure 90:

Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

118

Figure 91:

Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

119

Figure 92:

Asia-Pacific I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

120

Figure 93:

Asia-Pacific I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)

122

Figure 94:

Asia-Pacific I.V. Iron Drug Market, Country Share, 2016 (% of Total)

123

Figure 95:

Asia-Pacific I.V. Iron Drug Market, Country Share, 2022 (% of Total)

123

Figure 96:

Japan I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

124

Figure 97:

Japan Population 65 Years & Above (% of Total), 2012-2016

125

Figure 98:

Japan Life Expectancy at birth rate (Years), 2012-2015

125

Figure 99:

Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)

125

Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

126

Figure 100:

(c) AZOTH Analytics

22

List of Figures Figure No.

Figure Title

Page No.

Figure 101:

Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

127

Figure 102:

Japan I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

128

Figure 103:

China I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

130

Figure 104:

China Population 65 Years & Above (% of Total), 2012-2016

131

Figure 105:

China Life Expectancy at birth rate (Years), 2012-2015

131

Figure 106:

China Women Population, 2012-2016

131

Figure 107:

China Per Capita Healthcare Expenditure, 2012-2014 (In USD)

131

Figure 108:

China I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

132

Figure 109:

China I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

133

Figure 110:

China I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

134

Figure 111:

Registered Number Dialysis patients in China (In ten thousands), 2012-2016

135

Figure 112:

India I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

136

Figure 113:

India Population 65 Years & Above (% of Total), 2012-2016

137

Figure 114:

India Life Expectancy at birth rate (Years), 2012-2015

137

Figure 115:

India Women Population, 2012-2016

137

Figure 116:

India Per Capita Healthcare Expenditure, 2012-2014 (In USD)

137

Figure 117:

India I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

138

Figure 118:

India I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

139

Figure 119:

India I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

140

Figure 120:

Rest of Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

142

(c) AZOTH Analytics

23

List of Figures Figure No.

Figure Title

Page No.

Figure 121:

ROW I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)

144

Figure 122:

ROW I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)

145

Figure 123:

ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)

146

Figure 124:

ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)

147

Figure 125:

ROW I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)

148

Figure 126:

ROW I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)

149

Figure 127:

ROW I.V. Iron Drug Market, Country Share, 2016 (% of Total)

150

Figure 128:

ROW I.V. Iron Drug Market, Country Share, 2022 (% of Total)

150

Figure 129:

Brazil I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

151

Figure 130:

Brazil Population 65 Years & Above (% of Total), 2012-2016

152

Figure 131:

Brazil Life Expectancy at birth rate (Years), 2012-2015

152

Figure 132:

Brazil Women Population, 2012-2016

152

Figure 133:

Brazil, Per Capita Healthcare Expenditure, 2012-2014 (In USD)

152

Figure 134:

South Africa I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)

153

Figure 135:

South Africa Population 65 Years & Above (% of Total), 2012-2016

154

Figure 136:

South Africa Life Expectancy at birth rate (Years), 2012-2015

154

Figure 137:

South Africa Women Population, 2012-2016

154

Figure 138:

South Africa Per Capita Healthcare Expenditure, 2012-2014 (In USD)

154

Figure 139:

Percentage aged 60 years and over, (2000, 2015, 2030, 2050)

157

Figure 140:

Global Healthcare Expenditure, 2012-2016 (In Trillion)

159

(c) AZOTH Analytics

24

List of Figures Figure No.

Figure Title

Page No.

Figure 141:

Global Dialysis Patients, By Dialysis, 2016, (% Share)

160

Figure 142:

Global Dialysis Patients, 2012 -2016, Million

160

Figure 143:

Global Life expectancy at birth, total (years) 1990-2100

161

Figure 144:

Global Life expectancy at birth, total (years) 1990-2100

183

Figure 145:

Net Sales, By Region, 2016 (%)

183

Figure 146:

Revenue, 2013-2016 (USD Million)

183

Figure 147:

AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2012-2016

186

Figure 148:

Net Sales, By Business Unit, 2016 (%)

186

Figure 149:

AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2014-2016

190

Figure 150:

Net Sales, By Business Unit, 2016 (%)

190

Figure 151:

DAIICHI SANKYO Revenue, By Business segment, 2016 (%)

193

Figure 152:

DAIICHI SANKYO JAPAN BUSINESS, By Revenues, By Business segment, 2016 (%)

193

Figure 153:

DAIICHI SANKYO COMPANY, LIMITED Revenue (USD Million) 2012-2016

193

Figure 154:

NIPPON SHINYAKU CO., LTD, By Revenues, By Business segment, % Share Year Ending March 31st 2017 (%)

196

Figure 155:

NIPPON SHINYAKU CO., LTD Revenue (USD Million) 2013-2017, Year Ending March 31st 2017

196

Figure 156:

NIPPON SHINYAKU CO., LTD Revenue, By Geography, % Share, Year Ending March 31st 2017

196

Figure 157:

NIPPON SHINYAKU CO., LTD, R & D Expenses, 2016 (%)

197

(c) AZOTH Analytics

25

List of Figures Figure No.

Figure Title

Page No.

Figure 158:

Sanofi Revenue, By Business segment, 2016 (%)

199

Figure 159:

Sanofi BUSINESS, By, Revenues, By Business segment, 2016 (%)

199

Figure 160:

Sanofi Revenue (USD Million) 2012-2016

199

Table A:

Available I.V. Iron formulations approved for use throughout the world

Table B:

Percentage of patients receiving chemotherapy as a part of their primary treatment, Persons, all ages, England 2013-

38

101

2014

(c) AZOTH Analytics

26

Research Methodology For our study on Global I.V. Iron Drug Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of I.V. Iron drug Market.

Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of various other end-user sectors.

Market sizing and growth in the forecast period (2017-2022) is estimated through product mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.

Report Focus: I.V. Iron Drug Market -By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others) -By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others) - By Region (North America, Europe, Asia Pacific, ROW), - By Country – (United States, Canada, United Kingdom, Germany, France, China, India, Japan, Brazil and South Africa) - Company Coverage (Galenica, AMAG Pharmaceuticals, Inc, PHARMACOSMOS A/S, Allergan PLC, DAIICHI SANKYO COMPANY, LIMITED, NIPPON SHINYAKU CO.,LTD, Sanofi )

Companies Contacted: Lupin Pharmaceuticals, Inc. (c) AZOTH Analytics

27

Global I.V. Iron Drug Market Overview Increasing prevalence of chronic kidney diseases, growing geriatric population, increasing incidences of dialysis coupled with advancement in the Intravenous Iron Drug therapies propelled the market growth Figure : Global I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million) CAGR 2012-2016

I.V. Iron Drug: xx%

2012

2013

2014

2015

2016

Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx Xxxx Xxxx xxxx

(c) AZOTH Analytics

28

Global I.V. Iron Drug Market- By Product Type, By Value Figure : Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million) CAGR 2017-2022 Ferric carboxymaltose: xx%; Iron Sucrose: xx%; Iron Dextran: xx%: Others: xx%

CAGR 2012-2016 Ferric carboxymaltose: xx%; Iron Sucrose: xx%; Iron Dextran: xx%; Others: xx%

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx Xxxx xxxx

(c) AZOTH Analytics

29

North America I.V. Iron Drug Market- By Country Share

Figure : North America I.V. Iron Drug Market,

Figure : North America I.V. Iron Drug Market,

Country Share, 2016 (% of Total)

Country Share, 2022 (% of Total)

Brazil

Source: Azoth Analytics Estimates

Brazil

South Africa

South Africa

Source: Azoth Analytics Estimates

(c) AZOTH Analytics

30

Europe I.V. Iron Drug Market- By Therapeutic Application Availability of large number of I.V. iron for the treatment of Iron deficiency among kidney disease patients

attributed to the larger market share of I.V. Iron drug in nephrology segment

Figure : Europe I.V. Iron Drug Market Size, By

Key Drivers

Therapeutic Application, 2016 (%)

Nephrology Xxxx Gynecology & Obstetrics

xxxx

Gastroenterology

Oncology

Cardiology Xxxx Others

xxxx

Source: Azoth Analytics Estimates

(c) AZOTH Analytics

31

ROW I.V. Iron Drug Market- By Therapeutic Application, By Value Figure : ROW I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million) CAGR 2012-2016

CAGR 2017-2022

Nephrology: xx%; Gynecology & Obstetrics:

Nephrology: xx%; Gynecology & Obstetrics:

xx%; Gastroenterology; xx%; Oncology: xx%;

xx%; Gastroenterology; xx%; Oncology: xx%;

Cardiology: xx%; Others: xx%

Cardiology: xx%; Others: xx%

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx xxxx

(c) AZOTH Analytics

32

About Azoth Analytics Pvt Ltd. Azoth Analytics creates in-depth research reports by recording, interpreting and analyzing information through primary and secondary research. Our strategic market sizing and data dredging techniques include secondary research, interviews with key market players and industry experts and use of industry specific statistical tools which helps in designing and planning effective research for our global and local clients. We provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, retail, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors .

Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.

(c) AZOTH Analytics

33